Prostate Cancer

During a live virtual event, Alicia Morgans, MD, MPH, discussed when to combine novel hormonal agents with androgen-deprivation therapy in nonmetastatic castrate-resistant prostate cancer and how novel imaging techniques could influence treatment.

Prostate cancer expert Dr Smith elaborates on treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on systemic therapy.

Matthew R. Smith, MD, PhD, shares his personal experience using darolutamide for patients with prostate cancer.

Dr Matthew Smith discusses next generation androgen receptor inhibitors and data from clinical trials with these agents.

Prostate cancer expert, Matthew R. Smith, MD, PhD, shares his thoughts about importance of testing in treatment of metastatic castration-resistant prostate cancer (mCRPC).

Dr Matthew R. Smith reviews initial treatment options for a patient with metastatic castration-resistant prostate cancer (mCRPC).

An expert in prostate cancer discusses the typical follow-up and monitoring approaches for a patient with metastatic CRPC.

Matthew R. Smith, MD, PhD, presents the case of a 82-year-old man with metastatic castration-resistant prostate cancer (mCRPC) and shares his initial impressions.

After 8 months on enzalutamide, a 75-year-old patients with metastatic castration-resistant prostate cancer showed a PSA level of 60.7 ng/mL, enlargement of known pelvic lymph nodes, and progressive disease.

During a live virtual event, Alicia Morgans, MD, MPH, discussed the choice of novel hormonal agents to combine with androgen-deprivation therapy in nonmetastatic castrate-resistant prostate cancer.

During a live virtual event, Alicia Morgans, MD, MPH, discusses the appropriate usage of new genetic testing and PSMA scans in nonmetastatic castration-resistant prostate cancer.

Investigators set out to determine the relationship between prostate-specific antigen response and urinary and bowel adverse events, QOL deterioration, and prostate cancer-related invasive procedures.

Tanya Dorff, MD, asks the participants of a roundtable discussion about their opinion survival data of androgen receptor–targeted therapy and treating patients with PET scan-only metastatic castration-resistant prostate cancer.

A 75-year-old patient with metastatic castration resistant prostate cancer experienced an increase hip pain and urinary frequency 12 months after external beam radiation therapy plus androgen deprivation therapy.

Tanya Dorff, MD, asks the participants of a roundtable discussion which novel hormonal therapy they would choose in a patient with nonmetastatic castration-resistant prostate cancer.

Tanya Dorff, MD, asks the participants of a roundtable discussion what they would recommend as next-line therapy for a patient with nonmetastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, discusses the PSA response rate and adherence rate of a real-world study of apalutamide in patients with prostate cancer across 63 United States urology practices.

Tanya Dorff, MD, asks the participants of a roundtable discussion if they would order germline testing and molecular imaging in a patient with nonmetastatic castration-resistant prostate cancer.

Scott T. Tagawa, MD, FACP, shares clinical pearls and advice for the management of mCRPC.

An expert in prostate cancer comments on emerging agents and combinations in the pipeline for the treatment of mCRPC.

Scott T. Tagawa, MD, FACP, shares his thoughts on remaining questions for imaging and PSMA-targeted therapy for mCRPC.

Dr Scott T. Tagawa discusses common adverse events associated with 177Lu-PSMA-617 in patients with mCRPC and how to appropriately manage them.

A prostate cancer expert considers clinical implications from the phase 3 VISION study, including the potential role of 177Lu-PSMA-617 therapy for patients with mCRPC.

Scott T. Tagawa, MD, FACP, reviews the phase 3 VISION trial evaluating the use of 177Lu-PSMA-617 therapy in patients with mCRPC.

An expert in prostate cancer reviews available options for the treatment of mCRPC and considerations for selecting the optimal therapy.